富马酸伏诺拉生治疗反流性食管炎对患者血清炎症因子水平的影响

Effect of vonoprazan fumarate on serum inflammatory factors in patients with reflux esophagitis

目的探讨富马酸伏诺拉生治疗反流性食管炎患者对血清炎症因子水平的影响。方法选取2021年5月至2023年3月苏州一〇〇医院收治的80例反流性食管炎患者,按随机数表法分为观察组(富马酸伏诺拉生治疗,n=40)和对照组(奥美拉唑治疗,n=40)。比较2组的治疗效果、不良反应及治疗前后的胃食管反流病问卷(GERDQ)、胃肠道症状积分量表(GIS)评分及血清促胃液素(GAS)、血管活性肠肽(VIP)、肿瘤坏死因子‑α(TNF‑α)、白细胞介素‑6(IL‑6)、白细胞介素‑8(IL‑8)水平,门诊随访2组治疗后6个月复发情况。结果观察组总有效率高于对照组(P<0.05)。2组治疗后GERDQ评分、GIS评分低于治疗前,观察组低于对照组(P<0.05)。2组治疗后GAS高于治疗前,观察组高于对照组;VIP低于治疗前,观察组低于对照组(P<0.05)。2组治疗后TNF‑α、IL‑6、IL‑8低于治疗前,观察组低于对照组(P<0.05)。2组不良反应总发生率差异无统计学意义(P>0.05)。无失访患者,观察组复发率为2.50%(1/40),对照组为7.50%(3/40),差异无统计学意义(χ^(2)=0.263,P=0.608)。结论富马酸伏诺拉生治疗反流性食管炎,患者咽喉反流症状、胃肠激素及血清炎症因子水平均得到改善,远期疗效较好。

Objective To investigate the effect of vonoprazan fumarate on serum inflammatory factors in patients with reflux esophagitis.Methods Eighty patients with reflux esophagitis who were admitted to the Suzhou 100 Hospital from May 2021 to March 2023 were enrolled and divided into observation group(treated with vonoprazan fumarate,n=40)and control group(treated with omeprazole,n=40)according to the random number table method.The treatment efficacy,adverse reactions,Gastroesophageal Reflux Disease Questionnaire(GERDQ)score,gastrointestinal symptom score(GIS),serum gastrin(GAS),vasoactive intestinal peptide(VIP),tumor necrosis factor‑α(TNF‑α),interleukin(IL)‑6,IL‑8,and the recurrence within 6 months after treatment were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group(P<0.05).GERDQ score and GIS after treatment were lower than those before treatment in both groups,and the GERDQ score and GIS after treatment in the observation group were lower than those in the control group(all P<0.05).GAS after treatment was higher than that before treatment in both groups,and GAS after treatment in the observation group was significantly higher than that in the control group(all P<0.05).VIP,TNF‑α,IL‑6 and IL‑8 after treatment were significantly lower than those before treatment in both groups,and after treatment these parameters in the observation group were significantly lower than those in the control group(all P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).No patients were lost during follow up.The recurrence rate was 2.50%(1/40)in the observation group and 7.50%(3/40)in the control group(χ^(2)=0.263,P=0.608).Conclusion In treating reflux esophagitis with vonoprazan fumarate,the pharyngeal reflux,gastrointestinal hormones,and serum inflammatory factor levels can be improved,and the long‑term efficacy is satisfactory.